TYPT.F Stock Overview
Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Tryptamine Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.01 |
| 52 Week High | AU$0.01 |
| 52 Week Low | AU$0.005 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| TYPT.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.0% | -2.7% | -1.6% |
| 1Y | n/a | 17.6% | 19.8% |
Return vs Industry: Insufficient data to determine how TYPT.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how TYPT.F performed against the US Market.
Price Volatility
| TYPT.F volatility | |
|---|---|
| TYPT.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: TYPT.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine TYPT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Jason Carroll | www.tryptherapeutics.com |
Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company’s program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications.
Tryptamine Therapeutics Limited Fundamentals Summary
| TYPT.F fundamental statistics | |
|---|---|
| Market cap | US$20.29m |
| Earnings (TTM) | -US$3.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.2x
P/E RatioIs TYPT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TYPT.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$4.49m |
| Earnings | -CA$4.49m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0031 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -90.5% |
How did TYPT.F perform over the long term?
See historical performance and comparison